Yamaguchi, Tomokazu
Hoshizaki, Midori
Minato, Takafumi
Nirasawa, Satoru
Asaka, Masamitsu N.
Niiyama, Mayumi
Imai, Masaki http://orcid.org/0000-0001-6988-1975
Uda, Akihiko
Chan, Jasper Fuk-Woo
Takahashi, Saori http://orcid.org/0000-0001-7970-7647
An, Jianbo
Saku, Akari
Nukiwa, Ryota
Utsumi, Daichi http://orcid.org/0000-0001-6602-8426
Kiso, Maki
Yasuhara, Atsuhiro
Poon, Vincent Kwok-Man
Chan, Chris Chung-Sing http://orcid.org/0000-0001-7089-4829
Fujino, Yuji
Motoyama, Satoru
Nagata, Satoshi http://orcid.org/0000-0001-9156-5215
Penninger, Josef M. http://orcid.org/0000-0002-8194-3777
Kamada, Haruhiko
Yuen, Kwok-Yung http://orcid.org/0000-0002-2083-1552
Kamitani, Wataru
Maeda, Ken http://orcid.org/0000-0002-3488-5439
Kawaoka, Yoshihiro http://orcid.org/0000-0001-5061-8296
Yasutomi, Yasuhiro http://orcid.org/0000-0001-8252-1448
Imai, Yumiko http://orcid.org/0000-0003-4615-4833
Kuba, Keiji http://orcid.org/0000-0002-2203-5293
Funding for this research was provided by:
Japan Agency for Medical Research and Development (24-136)
MEXT | Japan Society for the Promotion of Science (20H03426, 20K21566)
Article History
Received: 12 September 2020
Accepted: 4 November 2021
First Online: 23 November 2021
Competing interests
: J.M.P. is shareholder of Apeiron Biologics which is developing soluble ACE2 (APN01) for COVID-19 therapy. There are no competing interests for other authors.